Osteoarthritis of the knee
Conditions
Interventions
Group A:After surgery, celecoxib 200mg, pregabalin 150mg, and nefopam 40mg were given orally, twice daily
Group B:After surgery, celecoxib 200mg, pregabalin 150mg, and placebo were given orally, twice daily
Sponsors
Department of Orthopaedics Surgery, West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients requiring primary unilateral TKA due to severe osteoarthritis of the knee; 2. Aged 18 to 80 years; 3. The American Society of Anesthesiologists (American Society of Anesthesiologists, ASA) classification (anesthesia risk assessment) is I~III level.
Exclusion criteria
Exclusion criteria: 1. Patients with heart, lung and other important organ failure; 2. Abnormal liver and kidney function (ALT and AST> 1.5 times of normal value, blood BUN>-8.3 mmoll, blood Scr>115 umol/L); 3. Patients with diabetes mellitus and poorly controlled blood glucose level who are at risk of infection according to researchers; 4. Combined with consciousness disorder or mental illness; 5. Have a history of open knee surgery; 6. Neuromuscular dysfunction affecting lower extremity function; 7. Patients with severe coagulation disorder; 8. Complicated with serious internal or surgical disease or weak constitution, unable to tolerate surgery; 9. Severe instability that cannot be cured by TKA with ligament preservation; 10. There are active infection foci in the body (systemic or local infectious lesions); 11. Severe osteoporosis, metabolic bone disease, radioactive bone disease and tumor around the knee joint; 12. Family planning, lactation and pregnancy women throughout the clinical study period; 13. Those who have participated in other clinical trials within 3 months; 14. Those who are deemed unsuitable for this clinical trial by the researcher for other reasons; 15. Knee flexion deformity >=30 degrees or internal and external varus deformity >=30 degrees; 16. Patients who are allergic to drugs used in this study; 17. Patients addicted to opioids; 18. Patients with language impairment and inability to complete the Visual analogue scale (VAS).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative morphine consumption; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time to first postoperative remedial analgesia;Postoperative visual analog pain score;Range of knee motion;Daily walking distance;Length of stay;Incidence of complications; | — |
Countries
China
Contacts
Public ContactKang Pengde
Outcome results
None listed